CML - Not only BCR-ABL1 matters.

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• BCR-ABL1 fusion protein drives chronic myeloid leukemia (CML) pathogenesis and is the primary target of tyrosine kinase inhibitor (TKI) therapy.
• Despite TKI success, leukemic stem cell (LSC) persistence, drug resistance, and disease progression remain significant challenges in CML management.
• Emerging evidence highlights the role of BCR-ABL1-independent mechanisms and molecular aberrations in CML.

Purpose of the Study:

• To explore the role of molecular aberrations beyond BCR-ABL1 in CML pathogenesis and treatment resistance.
• To identify therapeutic strategies targeting LSC survival pathways for improved CML treatment outcomes.
• To understand clonal evolution patterns and the impact of early mutations on CML development.

Main Methods:

• Review of current literature on CML molecular pathology and therapeutic resistance mechanisms.
• Analysis of sequencing data identifying frequent molecular aberrations in CML, including chronic phase.
• Examination of serial samples to elucidate patterns of clonal evolution and mutation acquisition.

Main Results:

• Frequent molecular aberrations, including ASXL1, DNMT3A, and TET2 mutations, are identified in CML, affecting epigenetic regulation.
• Some mutations precede BCR-ABL1 acquisition, suggesting they act as co-factors in CML pathogenesis.
• Clonal evolution patterns indicate complex genetic landscapes influencing disease progression.

Conclusions:

• Targeting pathways independent of BCR-ABL1 is crucial for disrupting LSC survival and overcoming TKI resistance.
• Understanding co-mutations and clonal evolution can inform future therapeutic strategies for CML.
• Further research into these additional molecular events may lead to improved treatment-free remission rates and functional cures in CML.